Heated chemo plus targeted drug shows promise in ovarian cancer trial

NCT ID NCT07460180

Recruiting now Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new approach for advanced ovarian cancer. Patients take a targeted drug (olaparib) for a week before surgery, then receive heated chemotherapy directly in the abdomen during the operation. The goal is to see if this combination is safe and effective. The trial involves 55 adults with stage III or certain stage IV ovarian, fallopian tube, or peritoneal cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Olaparib (a PARP inhibitor) combined with cisplatin chemotherapy and hyperthermia during surgery
What this could lead to: If successful, this could lead to a more effective treatment for advanced ovarian cancer by combining a targeted drug with heated chemotherapy during surgery.
What could go wrong: This is an early phase 1/2 trial with only 55 participants, so results may not apply broadly. The combination may cause unexpected side effects or not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma fallopian tube cancer fallopian tube neoplasm fallopian tube serous adenocarcinoma ovarian cancer ovarian serous adenocarcinoma peritoneal serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPITHELIAL CANCER FALLOPIAN TUBE CANCER OVARIAN CANCER

Contacts and locations

Locations

NKI-AvL
RECRUITING

Amsterdam, 1066CX, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.